Inter-assay variation of antibody based routine tests is hampering comparability of measurement results for growth hormone (GH) between different laboratories and decision making in clinical practice. Here it is demonstrated, that quantification of GH by isotope dilution mass spectrometry (IDMS) constitutes a way to precise and reliable results which can be referred to in evaluation of performance of commercial test kits. With the IDMS method developed, tryptic cleavage products YSFLQNPQTSLCFSESIPTPSNR (T6) and LEDGSPR (T12) of GH are quantified by LC/MS-MS using the isotopically labeled forms of the peptides as internal standards. The GH cleavage fragments are obtained by whole-serum tryptic proteolysis and then extracted from the resulting mixture by semi-preparative reversed phase liquid chromatography followed by strong cation-exchange chromatography. Method validation basing on recovery of recombinant 22 kDa GH, spiked to blank serum in defined amounts covering the intended concentration range 3 µg/L to 30 µg/L, would yield mean recoveries of 101.6% (100.7%), standard deviations (SD) of 2.5% (2.4%) and combined uncertainties (uc) of 3.0% (2.5%) if quantifying T6 (T12) as GH derived fragments, while the LOQ were 1.7 µg/L (2.7 µg/L). Potential to acquisition of reference values is exemplified by application to serum materials used in a recent quality assessment exercise for routine laboratories.
Introduction
Diagnosis of growth hormone (GH) deficiency and -excess (acromegaly) is based on determination of circulating concentrations of GH in serum during dynamic tests [1, 2] . In spite of efforts to standardization, decision making in clinical practice continues being hampered by significant discrepancies in assay results between different laboratories (test methods). The variation is attributed mainly to different specificities of the antibodies used, varying degree of recognition of GH-dimers, differences in recovery of GH being associated with growth hormone binding protein (GHBP), as well as matrix interferences in general [3] . While part of the sources, in order to be eliminated are requiring a more explicit definition of the measurand (e.g. epitope/isoform to be targeted), material improvement as to the analytical quality of results can be expected by just taking advantage of selectivity and reliability attainable by isotope dilution mass spectrometry (IDMS).
With small molecular diagnostic markers, IDMS has been a well established reference measurement principle for almost 40 years [4] [5] [6] . However, in spite of earlier model experiments to extend the scope of the technique to proteins [7] it was not until recently that quantification by IDMS of protein markers in body fluids for diagnostic purposes has been reported [8] [9] [10] [11] [12] [13] . Measurement of GH by MS has been discussed previously, namely in a feasibility study [14] , a discussion of MS as fast alternative method regarding the time needed for development of antibody based assays [15] and with an investigation about optimal conditions for proteolysis of serum samples [16] . Neither of the methods was applicable to measurement of samples in clinical practice at primary level, however, since no use was made of isotopically labeled internal standards and concentration ranges considered in these examples were far above what is relevant in clinical practice.
The present paper introduces an IDMS based quantification method which is applicable to samples with GH ranging from 3 µg/L to 30 (µg/L). Adopting a general strategy in quantitative proteomics [17] , tryptic cleavage products of GH are being quantified as signature fragments in place of GH as a whole. This way, the measurand, (whole-) GH, is represented by the amount-of-substance of the selected fragments. Labeled versions of these are added to the samples prior to proteolysis.
Sensitive detection of the targeted fragments is requiring effective separation from the complex proteolysis product. This is achieved by clean-up using two-step chromatography. The potential of the method to providing reference values is demonstrated with a set of sera which recently have been used in an external quality assurance scheme for clinical testing laboratories [18] .
Abbreviations: GH: growth hormone, GHBP: Growth hormone binding protein, IDMS: isotope dilution mass spectrometry, LC: liquid chromatography, LC/MS-MS: liquid chromatography-tandem mass spectrometry, ESI: electrospray-ionization, LOD: limit of detection, LOQ: limit of quantification, TFA: trifluoroacetic acid, RP: reversed phase, SCX: strong cation exchange, SPE: solid phase extraction, MRM: multiple reaction monitoring, Q1, Q3: GH reference solution and solutions of labeled peptide internal standards. A (stock-) reference solution of recombinant 22 kDa GH at 30.8 nmol/g (681 µg/g) in 1/1 (v/v), acetonitrile/water, was used for preparation of calibration solutions as well as for defined spiking of GH to serum samples used for method validation. Stock solutions of T6* and T12* used for additions of labeled internal standards were of 102.55 nmol/g and 146.81 nmol/g, respectively, in water. Concentrations of these solutions had been determined by amino acid analysis as described in a previous paper [19] .
Material used in method validation. Pooled human serum (NIST SRM (R) 971, female serum subset [20] ), was spiked with different amounts of GH to yield samples at (target-) concentrations of 0, 5, 10, 20 and 30 µg/L. A working solution obtained from the GH reference solution by dilution with acetonitrile/water, 1/1 (v/v), 0.1 M acetic acid, down to 22.12 pmol/g was used to this. Of this solution, 0, 5, 10, 20 and 30 mg were added to 500 µL aliquots of the serum. Samples were prepared in duplicate at each of the concentration levels resulting in eight GH-fortified samples to be analysed. No GH had been detectable with the pure serum (i.e., without addition) using the measurement protocol being described in this report.
Material used as example for method application. Samples from two serum pools (HP1/08 A and HP1/08 B), were obtained from DGKL, Referenzinstitut für Bioanalytik, D-53127 Bonn, Germany [18] . These were pooled human sera fortified with pituitary GH extract. Prior to IDMS analysis, the lyophilized material was reconstituted with 3 mL water per vial according to the suppliers protocol.
Calibration solutions. Calibration solutions were prepared by adding defined amounts of GH, T6* and T12* to 500 µL aliquots of water. The amounts to be added were chosen so as to mimic the concentration of GH expected with the serum sample to be analysed. Additions were made from working solutions obtained by dilution to 22.12 pmol/g of the (stock-) GH reference solution and the solutions of the labeled peptide internal standards.
Proteolysis. 500 µL of the sample (serum or calibration solution) were added to 12.1 mg TRIS base, 15.8 mg TRIS-HCL and 2.2 mg CaCl 2 (pH=8.2). To this, 50 µL of a solution containing 20 mg/mL trypsin in acetic acid (50 mM) were added and the sample was incubated at 37 • C. After 10, 30, 90, 150 and 210 min, respectively, another 50 µL aliquot of the trypsin solution was spiked into the reaction vial. In parallel, 100 µL of acetonitrile were added every 30 minutes starting at t=30 min, resulting in a final fraction of 58% acetonitrile after 330 min. The reaction was allowed to proceed for a total of 24h (1440 min). Following reductive cleavage of cysteine links (3.2 mg DTT, 1h at 37 • C) the non soluble fraction was removed by centrifugation (15 min at 17860 g).
The residue was extracted with 1 mL of acetonitrile/water, 1/1 (v/v), and the extract added to the filtrate from centrifugation. This was lyophilized and re-dissolved in 400 µL water. Again, the non Choice of GH-specific fragments. The cleavage fragments of GH used for quantification (T6 and T12) are shown in Fig. 1 . They were selected so as to selectively code for GH in complex matrix. BLAST search (BLASTP 2.2.21 database) and MS-Homology (UCSF Protein Prospector) were used for alignment and identification of potentially interfering cleavage products from other proteins. With T6, sequence alignment yielded exact matches exclusively with GH whereas in the case of T12 a second hit (caspase recruitment domain protein 9, isoform 2) additionally is returned.
In this protein, the T12 sequence is flanked by amino acids other than lysine and arginine, however, and trypsin does not release T12 as a fragment from it. Apart from about 1% glycosylation in the sequence range covered by T6, no posttranslational modifications are observed with GH in the regions of T6 and T12 [21] , so the mass spectrometric signals monitored virtually correspond to all of T6 and T12 present after proteolysis.
Method. The workflow of the method developed is shown in Fig. 2 . With each sample, a separate calibration solution is used as prepared by appropriate dilution from the (stock-) GH reference solution. The concentration is chosen in a range as close as possible to what is expected in the serum samples to be analyzed (which may require a preliminary analysis run for orientation).
GH-specific signature fragments (here: T6 and T12) are spiked as internal standards in isotopically labeled form (denoted as T6* and T12*) in equal amounts to both, serum sample and calibration solution. Exact matching [22] the analyte concentration of the sample with the calibration solution is on purpose to eliminate systematic errors that otherwise would result from uncertainty in knowledge of the degree of isotopic enrichment in the labeled internal standard used [23] . In order to ensure complete release of T6 and T12 from GH, sample and calibration solution are incubated for 24h at 37 • C in presence of 20 mg/L trypsin (water/acetonitrile, 2/3, v/v). Semi-preparative reversed phase liquid chromatography (RP-LC) followed by strong-cation-exchange (SCX) chromatography is used to separate the target peptides from the proteolysis product prior to analysis of signal ratios T6/T6* and T12/T12* by analytical scale RP-LC/MS-MS on a triple-quadrupole instrument. The amount of GH (two separate results: one using T6, another one for T12), is calculated based on comparison of the signal ratios obtained for that fragment in the sample and in the calibration solution, which corresponds to comparison of the amount of fragment generated from GH in the sample to the known amount generated from the calibration solution, since equal amounts of labeled internal standard had been spiked with both. The detailed protocols for proteolysis, extraction of T6,T6* and T12,T12* as well as analysis by mass spectrometry are provided in the corresponding subsections of Materials and Methods. Ion chromatograms from LC/MS-MS as obtained for a serum sample are shown in Fig. 3 .
Substance-and signal recovery of the signature fragments. Substance recoveries after extraction of T6,T6* and T12,T12* by two-step chromatography, as described, were found to be 61% with T6,T6* and 64% with T12,T12*. At the same time, signal recoveries were 14% (8%).
Curtailing the clean-up procedure by leaving out the SCX-chromatography step would result in a decrease of signal recoveries to 3% (1%).
Validation. Method performance was characterized based on evaluation of analytical recovery of defined amounts of GH spiked to a serum material which had been checked not to contain GH at a concentration detectable with the present method. Recombinant 22 kDa GH-reference solution was used for the additions, which previously [19] had been value-assigned by IDMS-based amino acid analysis. Eight samples were prepared at four different concentration levels ranging 4.5-30.5 µg/L. approach [24] was 0.5 µg/L (0.7 µg/L) and LOQ=1.7 µg/L (2.7 µg/L). Combination of mean bias, though not significant, and standard deviation (Table 1) is resulting in estimates of 3.0% (2.5%) as combined standard uncertainty (u c ) [25] attributable to the IDMS method.
Test for interference by GHBP. Effect of presence of GHBP on quantification results was investigated in a separate model experiment. Two solutions were processed according to the described protocol. Both were containing GH at 11.9 µg/L as well as T6* and T12* as internal standards. One of them additionally had been spiked with GHBP in 9-fold molar excess. There was no significant difference in signal ratios found in presence of GHBP and without: 1.00 (1.00) for T6/T6* and 0.91 (0.92) for T12/T12*.
IDMS measurement of GH in quality control materials. Samples from two serum pools, HP1/08 A and B, which recently had been used as test materials in an external quality assessment scheme [18] were re-analyzed by IDMS. Results were 7.07 (6.81) µg/L for pool A and 12.33 (12.28) µg/L for pool B with T6-(T12-) based quantification (means of n=3 runs, each). The data reported by 174 testing laboratories are visualized as Youden plots in Fig. 4(a-f) . For reference, the IDMS results are included. 
Discussion
GH as found in vivo is displaying considerable heterogeneity. It has been described to consist of several isoforms and variants resulting from modification of amino acid side chains, as well as forming dimers and even aggregates of higher order [21, 26] . Clear definition of the measurand, though vital with respect to comparability of measurements, is still subject to ongoing discussion in clinical chemistry. The present report is demonstrating the performance of IDMS as an analytical tool, given defined signature fragment(s) that are agreed upon to represent that measurand. Note, that specification of a cleavage fragment in many situations is similar to selecting an epitope on the surface of the protein. It may be anticipated therefore, that IDMS results correlate with those of antibody-based measurements depending on which epitope is being recognized by the antibody.
In this study, T6 and T12 were selected as examples. They are both present on 22 kDa GH, the most abundant isoform, as shown in Fig. 1 . Suitability of the two fragments to represent GH is further supported by the fact that virtually no posttranslational modification needs to be taken into account, so the mass spectrometric signals monitored should collect virtually all of T6,T6* and T12,T12* present after proteolysis.
The IDMS method reported is applicable to T6-(T12-) based serum measurement of GH in clinically relevant concentration. By measurement principle, IDMS has the potential to provide unbiased and reliable results at primary level of traceability to the SI [27] . This is supported by the performance data given in Table 1 . Standard deviations (2.5% and 2.4%, resp.) are as low as customarily attained in quantitative LC/MS, and, bias appears not to be significant (SD>mean bias in both cases, T6 and T12). Combining both components (repeatability and formally calculated bias), the uncertainties would be about 3% and making allowance for another 3% uncertainty in value assignment to the calibration material used, an overall estimate of u c ≈ 5% may be considered reasonable for the type of measurement.
Measurement of GH, since present in serum only at trace concentration level takes particular care in sample preparation so as to obtain instrumental responses of abundances enabling precise quantification. Owing to suppression of analyte signals by competition with matrix ions present at the same time [28] effective sample clean-up prior to measurement is crucial for quantification by ESI-MS. Extraction of the proteolytic fragments from the sample by specific antibodies [8, 9, 29, 30 ] is a promising approach to this. However, with the present method a chromatography-based alternative is used which seems to be quite as efficient while curtailing time and expense for production of antibodies. Performance data, in particular the limit of quantification (LOQ<3 µg/L) are at least
as good as what has been reported with antibody-based clean-up.
Using two-step chromatography (RP-LC plus SCX-) as described, signal recoveries were about 14% (8%) of what would have been obtained in complete absence of matrix-derived ions. Substance recoveries, at the same time, are 61% (64%). The effect of matrix suppression can be roughly estimated to be a factor 4-8 therefore, even after clean-up. Basically, improvement in substance recovery would be expected if leaving out one of the chromatography steps. However, the gain in substance recovery is outweighed by the accompanying increase in matrix suppression, as becomes manifest from the drop in signal recovery down to 3% (1%) if reducing analyte extraction to just RP-LC. Obviously, both steps are required for the procedure to achieve the reported performance (Table 1 ) and, in particular the LOD.
Interference by growth hormone binding protein, GHBP, as well as formation of GH-GH complexes are considered significant sources for disagreement of results between different immunoassays.
No such interference is expected to occur if applying fragment based quantification, as done here, unless proteolysis be obstructed by complex formation. However, this is not the case, as demonstrated with the GHBP interference test which yielded the same result in presence of GHBP as in absence. The IDMS method is capable of providing a measure of 'total' GH, obviously.
Considering the results obtained by the testing laboratories for the samples investigated in the external quality assurance exercise (Fig. 4 ) need for improvement is becoming evident. In both cases, pool A and pool B, significant part of the whole range in which GH concentrations are observed in clinical practice is covered by the spread of data. This would make clinical decision very difficult without reference to method dependent cut-off values, if these were real patient sera.
Referring to the results by IDMS the most striking discrepancy is the one to the values obtained by laboratories that were using the Siemens assay (Fig. 4a) . A good deal of this presumably is caused by lack of SI-traceability of the measurement: Many of these laboratories appear either not to have calibrated against the recommended international standard (WHO IS 98/574), which has been SI traceably value assigned [31] , or wrong factors have been used in converting mU/L to the required unit (µg/L). Apart from improper calibration, interferences by complex formation and recognition of non representative epitopes by the antibodies used cross selectivity towards non target antigens is among the potential causes for the deviations observed. In this situation, by the outstanding selectivity of MS if compared to the detection principles used with immunochemical tests, combined with reliability of IDMS in providing precise and SI-traceable results, the described method has the potential to produce target values for the routine assays which eventually might be considered for re-calibration of their results. In the present example, the DiaSorin (Fig. 4b ) test seems to be best in agreement with what is obtained by IDMS.
Though sufficient for GH quantification in materials presently used in quality control schemes and also in clinical samples seen during stimulation tests, improvement of the LOQ by about one order of magnitude would be required to extend the applicability to measure samples in patients during glucose suppression tests, where GH concentrations less than 1 µg/L are expected [32] . In terms of signal recovery, gaining a factor of 4-8 might be expected through complete elimination of ion suppression effects by further improvement of the clean-up procedure. However, a more promising option would consist of targeted enhancement of the analyte signals by appropriate conjugation of amino acid side chains so as to increase their basicity. For instance, a 6-fold increase in response factors has been reported on modifying cysteines with quaternary ammonium compounds [33] .
Increase of method sensitivity to enable application to samples from suppression tests appears to be possible therefore too.
Conclusion
The results reported are demonstrating that, by using IDMS the road is paved to acquisition of reference values for GH in serum at primary level of precision and reliability which are expected to be reproducible not just between different laboratories but also if another GH reference preparation should be used for calibration. The type of measurement is rendering a powerful tool for providing backup to antibody based measurements.
